New combo therapy trial for Tough-to-Treat skin cancers
Disease control
Terminated
This study tested whether adding an experimental drug called NT-I7 to an existing immunotherapy (atezolizumab) could help control advanced skin cancers. It focused on patients whose cancers had not responded to or had returned after similar treatments. The main goals were to find…
Phase: PHASE1, PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC